Inve India ▾

PI Industries share price & results

PI Industries Limited· Chemicals· Commodities

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Udaipur-based agrochemical & life-sciences maker: crop protection, CSM custom synthesis, pharma APIs.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue1,702 ₹ crore−10.4% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin22.0 %−5.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit244 ₹ crore−39.0% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity10.09 %−6.4 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-9.43 %−16.6 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)-16.57 %−19.9 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

1 of 6 judged targets kept · 10 open · verdicts reflect calls analysed to Q1 FY27.

PI Industries Limited management guidance track record on Inve: 16 targets tracked across analysed earnings calls (1 achieved, 5 missed, 10 open).

TargetOriginal wordingSaidLatest callVerdict
Consolidated EBITDA MarginAround 25%
Call transcript, Q4 FY25 · 20 May 2025		Q4 FY25Q1 FY27:Deadline passed. The target was achieved for FY26.
Call transcript, Q1 FY27 · 12 Aug 2026		Achieved
Overall Revenue GrowthMid single digit level growth this year (FY26)
Call transcript, Q4 FY25 · 20 May 2025		Q4 FY25Q1 FY27:Deadline passed. The target was missed for FY26.
Call transcript, Q1 FY27 · 12 Aug 2026		Missed
Pharma Business ProfitabilityPositive trends in FY27-FY28
Call transcript, Q4 FY25 · 20 May 2025		Q4 FY25Q1 FY27:Pharma business reported a ₹60 crore EBITDA loss, confirming it is not yet profitable. Management reiterates the long gestation J-curve for CRDMO investments.
Call transcript, Q1 FY27 · 12 Aug 2026		Delayed

Source: Inve Guidance Tracker for PI Industries Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

5 of PI Industries Limited's 16 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 13 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹2,020 −1.51% · −₹31

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance −43.6% 1Y

₹2.0k₹2.5k₹3.0k₹3.5kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 12 Nov 2025Q3 FY26 — 13 Feb 2026Q4 FY26 — 20 May 2026Q1 FY27 — 12 Aug 2026

1Y: ₹3,583.2 on 24 Oct 2025 → ₹2,020. High ₹3,820.5 (10 Nov 2025), low ₹2,020 (26 Oct 2026).

Previous close
₹2,051
Market cap
₹31.8k Cr
52-week range
₹2,020 – ₹3,820.5
One year
−44.04%
Price to earnings (TTM to Jun 2026)
29.46×
Return on equity (TTM to Jun 2026)
10.09%

Overview

Symbol
NSE:PIIND
Sector
Chemicals
Industry
Commodities
Exchange
NSE
Currency
INR

What PI Industries Limited does

Based on the company's own presentations, annual report and earnings calls.

PI Industries is an integrated life-sciences company operating across crop protection (agrochemicals), Custom Synthesis and Manufacturing (CSM)/CRDMO services for global innovator companies, biologicals, and pharmaceutical CDMO/API manufacturing. It designs, formulates and manufactures its own branded agrochemical products (insecticides, fungicides, herbicides, biologicals) for Indian farmers while also acting as a contract research, development and manufacturing partner to multinational agrochemical and health-science innovators. Through subsidiaries Jivagro Limited (horticulture-focused agri solutions, acquired 2019), Plant Health Care (PREtec peptide-based biologicals) and PI Health Sciences/Therachem (pharma CDMO and APIs), it has extended from pure-play Indian agrochemicals into biologicals and health sciences.

Segments

  • Crop protection (Agrochemicals)
  • CSM/CRDMO (Custom Synthesis & Manufacturing)
  • Biologicals
  • Pharma (CDMO/API)
Manufacturing locations
8
Distributor network
15,000+
Retail touchpoints
1,00,000+
Employees worldwide
4,000+
Global/international offices
9
Geographic presence
6 continents, 40+ countries
Founded 1946Headquarters Udaipur, Rajasthan, India (registered office); corporate office in Gurugram, Haryana Company website

How the price took the results

close before → close after

Q1 FY27
−9.0%
12 Aug
Q4 FY26
−7.1%
20 May
Q3 FY26
−2.2%
13 Feb
Q2 FY26
−5.2%
12 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for PI Industries Limited

Free account: one company. Everything above stays public.

Write why you follow PI Industries Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Chemicals companies

All Chemicals companies → · Chemicals earnings growth →

Learn to analyse PI Industries Limited

Guides on how to read this kind of business and the numbers that matter.